Closing 37% up for the week with strong investor anticipation for the Nasdaq dual listing in coming weeks Prima Biomed will be on everyone's watchlist now, and for a very good reason to. CVac, Prima's principle product uses a very similar technology to Nasdaq listed Dendreon's Provenge and the rise of Dendreon's share price during phaselll trials was quite significant to say the least. US investors will be quick to recognise the similarities and their appetite for Prima Biomed will prove very hungry.
I have a price target of $1.10c by January 2012
John Bradbury, Marketing Director, ABDM Group Investments
Closing 37% up for the week with strong investor anticipation...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.8¢ | 31.0¢ | $897.5K | 2.872M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 79201 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 138883 | 3 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |